<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988555</url>
  </required_header>
  <id_info>
    <org_study_id>DSP-5336-101</org_study_id>
    <nct_id>NCT04988555</nct_id>
  </id_info>
  <brief_title>A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients With and Without Mixed Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/2 dose escalation / dose expansion study of DSP 5336 in patients with relapsed or&#xD;
      refractory AML.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 (dose escalation) will determine the recommended Phase 2 dose (RP2D) (i.e. the lowest&#xD;
      dose of DSP 5336, that provides the maximum biologic and clinical effect, or the MTD,&#xD;
      whichever is lower) in adult patients with relapsed or refractory AML or ALL.&#xD;
&#xD;
      Phase 2 dose-expansion will further evaluate the safety and clinical activity of DSP 5336 in&#xD;
      adult patients with relapsed or refractory MLLr AML or NPM1m AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2022</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bayesian Regression Model for Phase 1 dose escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I Assess the safety and tolerability of DSP-5336 in relapsed/refractory AML or ALL</measure>
    <time_frame>Approximately 2 months after first dose</time_frame>
    <description>Occurrence of DLTs and frequency, duration and severity of TEAEs and SAEs assessed by NCI CTCAE v 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I Determine the RP2D based on lowest dose of DSP-5336 that provides the maximum biologic and clinical effect, or the MTD, whichever is lower.</measure>
    <time_frame>Approximately 2 months after first dose</time_frame>
    <description>Occurrence of DLTs and frequency, duration and severity of TEAEs and SAEs, plasma concentration-time profiles, changes in expression levels of biomarkers (gene expression levels).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 To evaluate clinical activity of DSP-5336 in adult patients with Relapsed /refractory AML who have MLL (KRMa gene rearrangement or NPM1 gene mutation)</measure>
    <time_frame>Approximately 6 months after first dose</time_frame>
    <description>Occurrence of CR, CRh, CR with MRD, EFS, RFS, TTR, DOR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I Preliminary clinical activity of DSP-5336 in adult patients with AML or ALL</measure>
    <time_frame>Approximately 6 months after first dose</time_frame>
    <description>Disease response as assessed by ELN 2017 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Phase 2 To further assess safety and tolerability of DSP-5336 in adult patients with Relapsed /refractory AML</measure>
    <time_frame>Approximately 2 months after first dose</time_frame>
    <description>Frequency, duration, and severity of TEAEs and SAEs assessed by NCI CTCAE v 5.0</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <condition>Leukemia, Lymphocytic, Acute</condition>
  <arm_group>
    <arm_group_label>Phase 1 Arm A without Antifungals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients not taking antifungals within 7 days of study entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Arm B with Antifungals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving anti-fungals that are moderate to strong cytochrome CYP3A4/5 inhibitors (i.e. Posaconazole, voriconazole, fluconazole)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm A AML with MLL (KMT2A) gene rearrangements</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with R/R AML w/MLL (KMT2A) gene rearrangements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm B: AML with NPM1c mutations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with R/R AML w/ NPM1c mutations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5336</intervention_name>
    <description>DSP-5336 orally</description>
    <arm_group_label>Phase 1 Arm A without Antifungals</arm_group_label>
    <arm_group_label>Phase 1 Arm B with Antifungals</arm_group_label>
    <arm_group_label>Phase 2 Arm A AML with MLL (KMT2A) gene rearrangements</arm_group_label>
    <arm_group_label>Phase 2 Arm B: AML with NPM1c mutations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Have a diagnosis of relapsed or refractory AML or ALL for Phase I and for Phase 2 have&#xD;
             a diagnosis of relapsed or refractory AML with MLLr or NPM1&#xD;
&#xD;
          2. Be &gt; 18 years of age or 20 years if required by local regulation&#xD;
&#xD;
          3. ECOG &lt; 2&#xD;
&#xD;
          4. WBC below 30,000/μL (hydroxyurea allowed prior to initiation of the study treatment)&#xD;
&#xD;
          5. Glomerular filtration rate (GFR) ≥ 50 ml/min, assessed by the Cockcroft-Gault formula&#xD;
&#xD;
          6. Total bilirubin ≤1.5 the upper limit of normal (ULN) (or ≤2.0 ULN for patients with&#xD;
             known Gilbert's syndrome)&#xD;
&#xD;
          7. Aspartate aminotransferase (AST) ≤3.0 times ULN&#xD;
&#xD;
          8. Alanine aminotransferase (ALT) ≤3.0 times ULN&#xD;
&#xD;
          9. Any prior treatment-related toxicities resolved to ≤Grade 1 prior to enrollment, with&#xD;
             the exception of ≤Grade 2 alopecia&#xD;
&#xD;
         10. Have an estimated life expectancy ≥3 months, based on the investigator's assessment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a left ventricular ejection fraction (LVEF) &lt;45%, as determined by ECHO&#xD;
&#xD;
          2. Histological diagnosis of acute promyelocytic leukemia&#xD;
&#xD;
          3. Received systemic calcineurin inhibitors within 4 weeks prior to the first dose of DSP&#xD;
             5336&#xD;
&#xD;
          4. Has had abnormal ECGs that are clinically significant, such as QT prolongation (QTc&#xD;
             &gt;450 msec for males and &gt;470 msec for females, with QTc corrected according to&#xD;
             Fridericia's formula [QTcF])&#xD;
&#xD;
          5. Has an active, uncontrolled, bacterial, viral, or fungal infection requiring systemic&#xD;
             therapy&#xD;
&#xD;
          6. Receives concurrent sensitive substrates with a narrow safety window or strong&#xD;
             inhibitors or inducers of CYP3A4/5, including specifically: ketoconazole, itraconazole&#xD;
             and isavuconazole. Other antifungals that are used as standard of care to prevent or&#xD;
             treat infections are permitted Also if a patient is on one of these excluded&#xD;
             antifungals he/she can be taken off or switched to a permitted azole 7 or more days&#xD;
             prior to first dose, then the patient could be allowed on study (Arm B)&#xD;
&#xD;
          7. Received immunotherapy, including tumor vaccines and checkpoint inhibitors, within 42&#xD;
             days prior to the first dose of DSP-5336&#xD;
&#xD;
          8. Has been on other investigational treatment within the previous 4 weeks prior to the&#xD;
             first dose of DSP-5336&#xD;
&#xD;
          9. Had major surgery within 28 days prior to the first dose of DSP-5336&#xD;
&#xD;
         10. Has active central nervous system leukemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacqueline Matczak</last_name>
    <phone>6176746800</phone>
    <email>jacqueline.matczak@sdponcology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keiichi Saito</last_name>
    <phone>8572703610</phone>
    <email>keiichi.saito@sdponcology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MDACC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Naval Davar, MD</last_name>
      <phone>713-794-4392</phone>
      <email>NDaver@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naval Davar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed or refractory AML</keyword>
  <keyword>MLLr</keyword>
  <keyword>Menin</keyword>
  <keyword>NPM1m</keyword>
  <keyword>KMT2A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

